Stratifin (SFN) is a multifunctional adapter protein that regulates diverse signaling pathways through phosphoserine/phosphothreonine-dependent binding to numerous partners 1234. As a p53-regulated cell cycle checkpoint protein, SFN inhibits G2/M progression 5 and may activate p53 by regulating MDM2 autoubiquitination 6. In epithelial cells, SFN maintains desmosome adhesion by sequestering PKP3 to the cytoplasm and facilitating PKP3 exchange at desmosome plaques, thereby preserving keratinocyte intercellular adhesion 78. SFN also suppresses innate immunity by binding phosphorylated GBP1, promoting its cytosolic retention 4. Clinically, SFN dysregulation associates with multiple cancers. In ovarian cancer, elevated SFN correlates with worse overall and post-progression survival, particularly in chemotherapy-treated patients 9. In breast cancer, SFN overexpression functions within a ceRNA network and serves as a potential prognostic biomarker 10. In chr1 kidney disease, SFN promotes renal fibrosis by interacting with MYH9 in renal tubular epithelial cells 11. Conversely, sulforaphane (a dietary compound distinct from the SFN protein) exhibits therapeutic potential in psoriasis, diabetic wound healing, and osteosarcoma through antioxidant and anti-inflammatory mechanisms 121314. These findings highlight SFN's dual role as both a critical cell homeostasis regulator and a potential oncogenic driver requiring targeted therapeutic intervention.